TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00381641
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02337634
Drug: Milk Thistle
Normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Study: NCT00484926
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: stopping clopidogrel at 1 year after DES
Study: NCT00484926
Drug: Aspirin,Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: continue aspirin and clopidogrel 1year after DES
Study: NCT01005784
Drug: Cetrorelix (Cetrotide)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible antagonist administration according to specified criteria
Study: NCT01005784
Drug: Cetrorelix (Cetrotide)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fixed antagonist administration on day 6 of ovarian stimulation
Study: NCT02812641
Drug: BPF-CCRT (run-in)
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If \> 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
Study: NCT02812641
Drug: BPF-CCRT (randomized)
Normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-two patients will be planned to assign to the experimental arm
Study: NCT02812641
Drug: PF-CCRT (randomized)
Normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-two patients will be planned to assign to the active control arm
Study: NCT00828061
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
Study: NCT00828061
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
Study: NCT00408551
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00408551
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00408551
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04252963
Drug: MUCOLASE tablet (streptokinase • streptodornase)
Normalized name: streptodornase / streptokinase
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: streptokinase • streptodornase 5mg
Study: NCT01597297
Drug: BIIB041 (PR Fampridine)
Normalized name: FAMPRIDINE
DrugBank: BIIB021 (DB12359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Study: NCT02465437
Drug: JBT-101
Normalized name: JBT-101
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
Study: NCT00571103
Drug: acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 333mg tablets taken three times daily.
Study: NCT00540644
Drug: lenalidomide (Revlimid®)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg p.o. daily on days 1-21 of each 28 day cycle
Study: NCT00540644
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg p.o. Q.O.D.
Study: NCT01369745
Drug: dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dipyridamole 360 mg daily
Study: NCT01369745
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 5 mg daily
Study: NCT01369745
Drug: Z102
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 2.7 mg plus dipyridamole 360 mg daily
Study: NCT02163681
Drug: Hyperpolarized Helium-3 MRI of the chest
Normalized name: Helium
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
Study: NCT01067417
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally 2x200mg capsules once daily for 48 weeks
Study: NCT01073826
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01073826
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00563914
Drug: amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: associated with artesunate
Study: NCT04425681
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment of LM With osimertinb
Study: NCT04425681
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment of LM With Bevacizumab
Study: NCT02862938
Drug: NT-501 ECT implant
Normalized name: NT 501
DrugBank: Ciliary neurotrophic factor (DB05344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
Study: NCT02768792
Drug: pembrolizumab,
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
Study: NCT00225186
Drug: Visanne (SH T00660AA , BAY86-5258)
Normalized name: Glutathione-SH
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
Study: NCT00558298
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00552708
Drug: COREG CR
Normalized name: Coreg CR
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00552708
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00441870
Drug: 99mTC-EC20 (Folic acid-technetium 99m conjugate)
Normalized name: linoleic acids, conjugated
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
Study: NCT01537380
Drug: Cefazoline
Normalized name: Cefazoline
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
Study: NCT03173456
Drug: oxycodone/APAP
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen 5 mg-325 mg oral tablet
Study: NCT03173456
Drug: hydrocodone/APAP
Normalized name: HYDROCODONE BITARTRATE 5 mg / ACETAMINOPHEN 325 mg ORAL TABLET [HYDROCODONE/APAP]
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
Study: NCT00005049
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005049
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005049
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00361803
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topotecan
Study: NCT01050322
Drug: Lapatinib Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
Study: NCT00519584
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml 0.5%
Study: NCT00519584
Drug: dex
Normalized name: Dex
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg (2 ml)
Study: NCT00519584
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml 0.5%
Study: NCT00519584
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% saline; systemic and local
Study: NCT03025269
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
Study: NCT01439984
Drug: Clomipramine
Normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
Study: NCT04501952
Drug: RDV
Normalized name: Remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an intravenous infusion
Study: NCT03061188
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02521792
Drug: Palovarotene
Normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
Study: NCT01639248
Drug: ENMD-2076
Normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg per day in oral capsules in 28 day continuous cycles
Study: NCT00192777
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02571062
Drug: Fexinidazole
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03936153
Drug: abexinostat
Normalized name: Abexinostat
DrugBank: Abexinostat (DB12565)
Approvals — FDA: no, EMA: no, PMDA: no
Description: abexinostat tablet
Study: NCT00421083
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00139555
Drug: amlodipine/benazepril
Normalized name: AMLODIPINE/BENAZEPRIL
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00084227
Drug: Atovaquone/Proguanil
Normalized name: ATOVAQUONE/PROGUANIL
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02666001
Drug: BMS-663068
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-663068
Study: NCT02666001
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone
Study: NCT02666001
Drug: Buprenorphine and Norbuprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine and Norbuprenorphine
Study: NCT00685360
Drug: Delamanid
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
Study: NCT00436826
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were administered with cladribine tablets orally as cumulative dose.
Study: NCT00436826
Drug: Interferon-beta (IFN-beta)
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
Study: NCT03310632
Drug: Antroquinonol
Normalized name: Antroquinonol
DrugBank: Antroquinonol (DB12326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
Study: NCT02902042
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose determined in phase I. Start dose: 450 mg qd
Study: NCT02902042
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose determined in phase I. Start dose: 45 mg bid
Study: NCT02902042
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose determined in phase I. Start dose: 200 mg q3w
Study: NCT02902042
Drug: Pembrolizumab alone
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg q3w
Study: NCT03360214
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For active drug, 0.25% marcaine, will be used.
Study: NCT03360214
Drug: Ropivacaine Hydrochloride
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For active drug, 0.25% naropin, will be used.
Study: NCT01678664
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg per day of everolimus during 24 months or until progression disease
Study: NCT04553770
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00124722
Drug: Rocuronium bromide (Zemuron)
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
Study: NCT00124722
Drug: Rocuronium bromide (Zemuron)
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
Study: NCT00124722
Drug: Rocuronium bromide (Zemuron)
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
Study: NCT00102856
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00102856
Drug: Rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04291118
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
Study: NCT00666159
Drug: tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical
Study: NCT00666159
Drug: pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical
Study: NCT00758381
Drug: Gemcitabina, Cisplatino
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
Study: NCT04839666
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperatively propofol administration
Study: NCT00204061
Drug: Amisulpride
Normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
Study: NCT02497937
Drug: GSK2798745
Normalized name: GSK2798745
DrugBank: GSK2798745 (DB16033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
Study: NCT00671801
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
Study: NCT00671801
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
Study: NCT01091870
Drug: Sildenafil Citrate, 25 mg, 3 times a day.
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
Study: NCT03034837
Drug: resin sealant
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
Study: NCT03034837
Drug: ART sealant
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once.
Study: NCT00096538
Drug: valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02273362
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02273362
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02497508
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01822210
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: injection by gastroscopy (100 Allergen units)
Study: NCT00672633
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza , 4 grams/day orally for 6 months
Study: NCT00778791
Drug: metformin HC1 750 mg extended-release tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01938846
Drug: BI 860585
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 860585 multiple dose escalation, once daily
Study: NCT01938846
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane once daily
Study: NCT01938846
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel once weekly
Study: NCT03293017
Drug: Diazepam 10 MG
Normalized name: diazepam 10 MG
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
Study: NCT03293017
Drug: Baclofen 30mg
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 30 mg/day given over three gifts daily
Study: NCT03293017
Drug: Baclofen 60mg
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 60 mg/day given over three gifts daily
Study: NCT00929344
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
Study: NCT00929344
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
Study: NCT02714010
Drug: EGFR-TKI
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
Study: NCT03603119
Drug: Normal saline, Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery